Drug Profile
Ciclosporin ophthalmic - Santen SAS
Alternative Names: Ciclosporin - Santen SAS; Cyclokat; Cyclosporin - Santen SAS; Cyclosporine Ophthalmic Emulsion - Santen S.A.S; DE 076B; DE 076C; Ikervis; Nova 22007; STN-1007603; Vekacia; VerkaziaLatest Information Update: 19 Feb 2024
Price :
$50
*
At a glance
- Originator Novagali Pharma
- Developer Santen Pharmaceutical; Santen S.A.S.
- Class Anti-inflammatories; Antineoplastics; Antipsoriatics; Antirheumatics; Ciclosporins; Eye disorder therapies; Heart failure therapies; Neuroprotectants
- Mechanism of Action Calcineurin inhibitors; Free radical inhibitors; Immunosuppressants; Mitochondrial permeability transition pore inhibitors; P-glycoprotein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Allergic conjunctivitis; Dry eyes
Most Recent Events
- 16 Feb 2024 Apotex in-licenses exclusive rights for manufacturing and commercialization of ciclosporin ophthalmic from Harrow in Canada
- 29 Sep 2023 Harrow Health is now called Harrow
- 18 Jul 2023 Harrow Health in-licenses exclusive rights for manufacturing and commercialization of ciclosporin ophthalmic from Santen Pharmaceutical in the US and Canada